Trial Profile
A Phase 1 Open Label Study of the Safety and Pharmacokinetics of SM-03, an anti-CD22 antibody, in Chinese Systemic Lupus Erythematosus Subjects With Active Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2016
Price :
$35
*
At a glance
- Drugs Suciraslimab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors SinoMab Bioscience Ltd
- 18 Jul 2016 Results published in the Clinical Drug Investigation
- 21 Dec 2015 New trial record